User:PedsID

Dan M. Granoff (born January 22, 1944) is an infectious disease physician-scientist who was named the 2014 Maurice Hilleman/Merck Laureate by the American Society of Microbiology for outstanding contributions to vaccine discovery and development. Beginning in 2011, Granoff held the Clorox Foundation Endowed Chair and was Director of the Center of Immunobiology and Vaccine Development at Children’s Hospital Oakland Research Institute (Currently University of California San Francisco (UCSF) Children’s Hospital Oakland). He is the author or co-author of more than 225 research articles published in peer-reviewed journals, and his work has increased understanding of basic mechanisms of human immunity to encapsulated bacteria. His work furthered development of vaccines against Haemophilus influenzae type b (Hib) and Neisseria meningitis (also called the meningococcus).

Personal life
Granoff was born in 1944 in New York City, NY. He divides his time between San Francisco, California, and Carmel Valley, California, with his partner, Marjory A Kaplan, a retired lawyer. He was married to Alice Baghdassarian Granoff, M.D., and divorced in 1985. They have two sons Jonathan and Jeffrey Granoff.

Education
Granoff completed his bachelors and medical degrees at Johns Hopkins University, Baltimore Maryland. He completed Pediatric residency training at the Johns Hopkins Hospital, followed by a post-doctoral fellowship in Pediatric Infectious Diseases at Cleveland Metropolitan General Hospital (currently, MetroHealth Medical Center).

Community protection after vaccination (also referred to as "Herd immunity"
With Drs. Trudy Murphy (then at Southwestern Medical School Dallas) and Michael Osterholm (then Minnesota Health Departmen t) Granoff demonstrated how PRP-D (Hib capsular polysaccharide protein conjugate) vaccine decreased Hib disease in both vaccinated and unvaccinated children.

Effect of vaccination on asymptomatic Hib colonization of the nose and throat
Granoff and his colleagues demonstrated an unexpected decrease in the presence of Hib in the noses and throats of healthy children who had been immunized with PRP-D compared to unvaccinated children and children vaccinated with an earlier vaccine containing unconjugated polysaccharide. This finding provided the basis for the observed community protection associated with PRP-D vaccination.

Unexpected presence of mature B cells capable of responding to polysaccharide antigens in 2 month-old infants.
In 1986 Granoff and his colleagues reported that a single injection of a modified Hib conjugate vaccine elicited a protective antibody response in two month-old infants. Granoff’s findings proved that B cells, with the appropriate rearranged genes, were in fact present at age two months and were activated by a single injection of this Hib polysaccharide conjugate vaccine. This result was unexpected since scientists at the time believed that two-month-olds did not have mature B cells capable of responding to polysaccharide antigens.

Defining the structure and function of human antibody to Hib polysaccharide.
With Dr. Alexander H. Lucas, Granoff used idiotypic analysis to investigate variable region gene diversity in human antibodies for Hib polysaccharide. They found dramatic changes in gene utilization by age of vaccination, and different Hib vaccine types. Collectively these studies contributed to making anti-Hib capsular antibodies one of the best understood human antibody systems at a molecular level.

A meningococcal serogroup A conjugate vaccine for Sub-Saharan Africa.
In 1999, Granoff and his colleagues at the World Health Organization, proposed the feasibility of developing and manufacturing a low cost, meningococcal vaccine for Africa using a public–private partnership. As a result, in 2010, under the leadership of Dr. Marc LaForce, a low cost, vaccine, called MenAfriVac, was introduced in Sub-Saharan Africa. By the end of 2014, more than 150 million people had been immunized. The vaccine was shown to be highly effective in preventing group A epidemics. Critically, it decreased bacteria in the nose and throat, helping to establish herd immunity.

Discovery of the role of meningococcal Factor H binding protein in meningococcal pathogenesis.
Collaborating with Sanjay Ram’s Laboratory, then at Boston University School of Medicine, Granoff and colleagues found that a meningococcal lipoprotein is critical for the ability of the bacteria to survive in human serum. They renamed the liporprotein  “Factor H binding protein” or “FHbp”. FHbp is now the main or sole antigen in the two meningococcal serogroup B vaccines licensed in the U.S., Europe and in other areas of the world.

Low-FH binding mutants of FHbp
In immunized humans the FHbp antigen forms a complex with human FH. With Drs. Peter Beernink and Sanjay Ram, Granoff showed that FH binding to FHbp decreased protective antibody responses. Beernink and Granoff went on to create mutant FHbp vaccines with amino acid substitutions that decreased FH binding, which elicited greater protective antibody responses. They showed that, currently licensed FHbp-based meningococcal B vaccines can be improved by introducing these amino acid substitutions.

Meningococcal vaccines using native outer membrane vesicle (NOMV)
Granoff and his colleagues investigated over-expressing FHbp in NOMV prepared from mutant meningococcal strains. The meningococcal NOMV vaccine combined with over-expressing mutant low FH-binding FHbp elicited much higher and broader protective antibody responses than control vaccines, including a currently licensed one.

Publications
Granoff authored or co-authored more than 225 research articles in peer-reviewed journals, review articles, and multiple textbook chapters including recent chapters on Meningococcal vaccines published in the 7th edition of Plotkin’s Vaccines, Granoff also co-edited a textbook on Hib vaccines with Dr. Ronald D Ellis.

Academic and Business career
Granoff served as Director of the Division of Pediatric Infectious Diseases at Washington University School of Medicine and St. Louis Children’s Hospital from 1979 to 1993. In 1993, he  became Executive Director of Clinical Vaccine Research at Chiron Corporation (Emeryville CA) with a joint appointment as a Scientist at Children’s Hospital Oakland Research Institute (Currently UCSF Benioff Children’s Hospital)]. His team at Chiron was responsible for clinical development of the first adjuvanted influenza vaccine, and a meningococcal serogroup C conjugate vaccine used to control deadly outbreaks in the United Kingdom. In 1995 Granoff became Vice President of Scientific Affairs. He left Chiron in 1998 to become a Senior Scientist at Children’s Hospital Oakland Research Institute.

Editorships
Granoff served as Associate Editor of the journal, Pediatric Research (1982-1988) and currently is a member of the Editorial Boards of Human Vaccines and Immunotherapeutics and the journal Vaccine. He also is on the Editorial Advisory Board of the journal, Clinical Infectious Diseases.

The American Society for Clinical Investigation (ASCI)
Elected to membership in 1987.

The American Academy of Microbiology
Elected as a Fellow in 2010.

The Infectious Diseases Society of America and the Pediatric Infectious Diseases Society

Elected as a Fellow to both organizations.

1981 Alpha Omega Alpha
Faculty honoree at Washington University of Medicine, St. Louis

=== 2010 Stanley A. Plotkin Awardee in Vaccinology , the Pediatric Infectious Diseases Society === Granoff received this award for significant contributions to the field of “vaccinology.”

2014 Maurice Hilleman/Merck Laureate, the American Society of Microbiology
Granoff received this award for outstanding contributions to vaccine discovery and development.

=== 2017 Johns Hopkins School of Medicine Distinguished Medical Alumnus Award ===

Patents
Granoff is inventor or co-inventor on multiple US and international patents including Patent Nos. US6,936,261; US8,968,748; US9,034,345; US9,439,957; US10,857,221; and US10,905,754 and others.